Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relacorilant DDI study with Dabigatran
NCT05347979Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relacorilant in Cushing syndrome and Neoplasm, sponsored by Corcept Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration of Dabigatran, Area Under the Curve from Time 0 to Last Measurable Concentration of Dabigatran and 1 more. Started May 2022; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing syndromeNeoplasm
Beyond the preview
Go deeper on NCT05347979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05347979.